WMWilliam C. Merritt

William C. Merritt

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


William C. Merritt has a total of 29 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Characterization of Amnion-Derived Membrane for Clinical Wound Applications

    by Alison L. Ingraldi, Tim Allen, Joseph N. Tinghitella, William C. Merritt, Timothy Becker, Aaron J. Tabor

    Human amniotic membrane (hAM), the innermost placental layer, has unique properties that allow for a multitude of clinical applications. It is a common misconception that birth-derived tissue products, such as dual-layered dehydrated amnion–amnion graft (dHAAM), are similar regardless of the manufacturing steps. A commercial dHAAM product, Axolotl Biologix DualGraft™, was assessed for biological and mechanical characteristics. Testing of dHAAM included antimicrobial, cellular biocompatibility, proteomics analysis, suture strength, and tensile, shear, and compressive modulus testing. Results demonstrated that the membrane can be a scaffold for fibroblast growth (cellular biocompatibility), containing an average total of 7678 unique proteins, 82,296 peptides, and 96,808 peptide ion variants that may be antimicrobial. Suture strength results showed an average pull force of 0.2 N per dHAAM sample (equating to a pull strength of 8.5 MPa). Tensile modulus data revealed variation, with wet samples showing 5× lower stiffness than dry samples. The compressive modulus and shear modulus displayed differences between donors (lots). This study emphasizes the need for standardized processing protocols to ensure consistency across dHAAM products and future research to explore comparative analysis with other amniotic membrane products. These findings provide baseline data supporting the potential of amniotic membranes in clinical applications.


  • Open Access

    Large, Wide‐Neck, Side‐Wall Aneurysm Treatment in Canines Using NeuroCURE: A Novel Liquid Embolic

    by William C. Merritt, Nicholas Norris, Sophia Robertson, Mark C. Preul, Andrew F. Ducruet, Timothy A. Becker

    Background: Untreated intracranial aneurysms can rupture and result in high rates of morbidity and mortality. Although there are numerous approved endovascular aneurysm treatment devices, most require dual anti‐platelet therapy, are minimally biocompatible, or are prone to recanalization. Neurovascular Controlled Uniform Rapid Embolic (NeuroCURE) is an innovative polymer gel material with long‐term stability, biocompatibility, and hemocompatibility developed for the treatment of large, wide‐neck aneurysms. Methods: Sidewall aneurysms were surgically created in 10 canines and NeuroCURE was injected through a 0.025 microcatheter under a single balloon inflation period. Aneurysm treatment was angiographically assessed post‐embolization and pre‐term with Raymond–Roy occlusion classification and a qualitative flow grade scale. Aneurysm neck stability and biocompatibility was histologically assessed to grade platelet/fibrin thrombus, percent endothelialization, and neointimal formation. Aneurysm sac stability was assessed by NeuroCURE sac content, inflammation, and neo‐angiogenesis scales. Results: Explanted aneurysms exhibited a smooth surface at the aneurysm neck with nearly complete neointimal coverage at 3‐months. By 6‐months, neck endothelialization was 100% in all animals (average Raymond–Roy occlusion classification of 1.2), with no instances of aneurysm recanalization or parent vessel flow compromise. Biocompatibility assessments verified a lack of inflammatory response, neo‐angiogenesis, and platelet/fibrin thrombus formation. Conclusion: The NeuroCURE material promotes progressive occlusion of wide‐necked side wall aneurysms over time without the need for dual antiplatelet agents. NeuroCURE also promotes neointimal tissue infill without dependence on thrombus formation and thus resists aneurysm recanalization. NeuroCURE remains a compelling investigational device for the treatment of intracranial aneurysms.


  • Open Access

    O-058 PPODA as a mechanically stable and biocompatible coating for endovascular stents and flow diverters

    by S Robertson, W Merritt, T Becker, A Ducruet

    Introduction Endovascular flow diverters (FDs) and stents, comprised of shape memory (i.e. Nitinol) or cobalt alloys have limited long-term biocompatibility. Nitinol can leach genotoxic and allergy-inducing nickel ions. Current nitinol and metal alloys also exhibit inconsistent endothelialization across the aneurysm neck, often resulting in delayed aneurysm occlusion. PPODA-QT (NeuroCURE®) is a biocompatible polymer under development for endosaccular treatment of intracranial aneurysms. ISO-certified biocompatibility testing confirms NeuroCURE exhibits superior hemocompatibility (prevents thrombosis) and promotes continuous endothelial growth over the aneurysm neck within the first 6-months. In this study, we chemically bound a monolayer of PPODA to Nitinol wires to enhance mechanical stability and biocompatibility. Materials and Methods Oxygen-argon plasma treatment was used to prepare the surface of nitinol wires. Silanization with SH-PEG-Silane functionalized the surface to improve polymer adhesion. Inductively coupled plasma mass spectrometry (ICP-MS) and scanning electron microscopy (SEM) were used to verify presence of the silane layer. Surface-modified wires were coated by running a basic solution containing PPODA over the wire surface (figure 1a). The terminal thiol groups of the silane reacted with PPODA (Michael addition reaction - figure 1b). ICP-MS and SEM were used to evaluate polymer continuity and thickness. Polymer properties were then compared to parylene, an established polymer control coating applied via vapor deposition. The integrity of PPODA and parylene coatings was evaluated, via a DMA-rheometer (TA Instruments) in the Bioengineering Devices Lab (BDL) at Northern Arizona University (NAU). Shear, wire-on-wire delamination, and bending integrity at physiologically-relevant forces and shear rates were assessed, and SEM verified potential wire-polymer delamination effects. Results and Discussion SEM images showed variation in continuity among the different surface coatings and the controls (with or without surface modification, PPODA versus parylene). Mechanical testing suggested significant variations in adhesion of different coatings, helping to optimize the coating technique. Future work will finalize coating optimization and assess biocompatibility of control (uncoated) versus coated wires for in vitro endothelial cell growth, implantation effects, hemocompatibility, and metal ion leaching (Time-of-Flight Secondary Ion Mass Spectrometry - ToF-SIMS). Conclusion PPODA polymer coatings can improve biocompatibility and prevent thrombosis on FDs and stents by pre-coating wires for braiding or post-coating laser-cut stent devices. Future work will compare coating integrity and biocompatibility to established devices (i.e Pipeline Shield® and Fred-X®). Materials like PPODA may provide FDs and stents with a mechanically stable scaffold coating that promotes continuous re-endothelialization over an aneurysm neck, which can eliminate thrombosis and reduce recanalization rates. SH-PEG-Silane and PPODA bound to a nitinol wire surface. Figure la is an SEM image of a nitinol wire with these polymers attached and Figure 1b is a graphic depiction of this attachment Disclosures S. Robertson: 5; C; Northern Arizona University. W. Merritt: 1; C; SNIS Young Investigator Research Grant. 4; C; Aneuvas Technologies, Inc. 5; C; Aneuvas Technologies, Inc. T. Becker: 1; C; SNIS Young Investigator Research Grant. 2; C; United Biologics. 4; C; Aneuvas Technologies, Inc. 5; C; Northern Arizona University. A. Ducruet: 2; C; Medtronic, Penumbra, Oculus, Stryker, Balt, Koswire. 4; C; Aneuvas Technologies, Inc. 5; C; Barrow Neurological Institute.

  • Open Access

    E-075 Technical evaluation of aspiration using hard and soft synthetic clots

    by H Berns, O Asgari, J Wells, J Vigil, W Merritt, A Ducruet, T Becker

    Introduction/Purpose Aspiration thrombectomy is the standard of care for large vessel occlusions. Although clot composition and hardness are known to affect fragmentation risk during aspiration, the role that clot composition plays in digestion rates is not as well understood. The purpose of this study is to assess synthetic clot aspiration effectiveness for hard and soft clots. Materials and Methods Benchtop testing was performed to analyze the digestion rate of both hard (90% PAAM - ALG) and soft (83% PAAM - ALG) synthetic clot types. Synthetic clot aspiration digestion rates were assessed with the Bioengineering Devices Laboratory (BDL) benchtop flow model at Northern Arizona University (NAU). The model consists of a programmable, hydraulic pulsatile pump system (SuperPump AR, ViVitro Labs) that simulates physiological neurovascular flows and pressures. The benchtop system accommodates swappable 3D-printed circle of Willis (CW) flow models made from UV cured and acrylic-based co-polymers, which can replicate the mechanical properties of human vessels. The model also incorporates a novel and stable blood analog to mimic the viscosity and shear-thinning of blood, allowing real-time pressure and flow measurements at each CW branch. The two published synthetic blood clot analogs (soft and hard clots) were used to simulate clot aspiration. In the benchtop model, the aspiration catheters, Zoom 88 (Z88 – Imperative Care) and Sofia (MicroVention) were advanced to the MCA, connected to a Zoom aspiration pump (Imperative Care) and used to remove soft and hard clot analogs. Various properties were evaluated during clot ingestion – tip geometry, catheter-to-vessel ratio (CVR), real-time pressure measurements corresponding to aspiration force, clot integration imaging, clot digestion rate into the vacuum pump, and first-pass efficiency (FPE) determined by real-time branch flow measurements. Results Preliminary data from clot digestion rate suggest that the aspiration of hard synthetic clots correspond to greater clot integration and faster digestion rates while requiring less aspiration force. Larger-bore catheters with greater CVR can also enhance clot integration and digestion rates. Aspiration of soft synthetic clots corresponds to reduced clot integration and variable digestion rates with inconsistent FPE results. Conclusion The relationship between clot composition and digestion provides more context regarding clinical variations in aspiration efficacy, which may help to inform treatment decisions. Further testing will include Top: BDL-NAU benchtop flow model with real-time pressure and flow monitoring in each CW branch. A) hard clot lodged in Cavernous ICA B) catheter engaged with clot C) clot digested into catheter Disclosures H. Berns: None. O. Asgari: None. J. Wells: None. J. Vigil: None. W. Merritt: 4; C; Aneuvas Technologies, Inc.. 5; C; Aneuvas Technologies, Inc. A. Ducruet: 2; C; Medtronic, Penumbra, Oculus, Stryker, Balt, Koswire. 4; C; Aneuvas Technologies, Inc. 5; C; Barrow Neurological Institute. T. Becker: 4; C; Aneuvas Technologies, Inc.. 5; C; Aneuvas Technologies, Inc., Northern Arizona University.

  • Open Access

    E-053 Creation and characterization of synthetic polymer thrombus for thrombectomy device testing

    by J Vigil, H Berns, S Robertson, H Gaines, C West, D Roser, W Merritt, T Becker, A Ducruet

    Introduction Currently, whole blood clots used for medical device testing are created by drawing blood directly from a subject (typically swine or bovine), then conducting a rigorous centrifuge process and/or introducing chemical additives. In recent years, synthetic blood clots have been developed that can complement whole blood thrombi. The present study involves the creation of synthetic hard and soft clots mechanically matched to human and animal thrombus samples. Materials and Methods Polyacrylamide and alginate polymers (PAAM – ALG) were mixed at varying concentrations to achieve desired clot stiffness. After developing a manufacturing procedure for soft and hard clots, contrast agents were added during the polymer gelation process for radiopacity. The mechanical properties (compression and shear moduli) of all synthetic clots were assessed using a DMA-Rheometer (TA Instruments) at 40% compression, across a physiologically-relevant frequency range of 1-10 rad/s. Whole swine blood thrombi were also created and tested using the same mechanical testing methods. All clots were statistically compared to published human clot data. Results Whole swine blood thrombi represented soft clots, as the mechanical properties corresponded to an organized viscous fluid with minimal compressive and shear resistance. Mechanical testing data demonstrated that high alginate concentrations (83% PAAM - ALG) corresponded to soft clots, whereas high acrylamide concentrations (90% PAAM - ALG) represented hard clots. Imaging via fluoroscopy verified clot radiopacity using 20 vol% Conray® added during polymer gelation. Conclusion Polymer clots are ideal for benchtop testing, with increased shelf-life and minimal biohazard handling requirements when compared to animal blood clots. The polymer clots can be delivered to benchtop vessel models and used for surgical training and device testing. Synthetic clots show substantial promise for thrombectomy device testing as their mechanical properties can be tuned to replicate various whole blood clot types, and can be altered to include fibrous and calcified clot components. Disclosures J. Vigil: None. H. Berns: None. S. Robertson: None. H. Gaines: None. C. West: None. D. Roser: None. W. Merritt: 4; C; Aneuvas Technologies, Inc.. 5; C; Aneuvas Technologies Inc. T. Becker: 4; C; Aneuvas Technologies, Inc.. 5; C; Aneuvas Technologies Inc. A. Ducruet: 2; C; Medtronic, Penumbra, Oculus, Stryker, Balt, Koswire. 4; C; Aneuvas Technologies, Inc.

  • Application of nondestructive mechanical characterization testing for creating in vitro vessel models with material properties similar to human neurovasculature

    by Nicholas G. Norris, William C. Merritt, Timothy A. Becker

    Vessel models are a first step in developing endovascular medical devices. However, these models, often made from glass or silicone, do not accurately represent the mechanical properties of human vascular tissue, limiting their use to basic training and proof‐of‐concept testing. This study outlines methods to quantify human vascular tissue mechanical properties and synthetic biomaterials for creating representative vessel models. Human vascular tissue was assessed and compared to silicone and new UV‐cured polymers (VC‐A30) using the following eight mechanical tests: compressive, shear, tensile dynamic elastic modulus, Poisson's ratio, hardness, radial force, compliance, and lubricity. Half of these testing methods were nondestructive, allowing for multiple mechanical and histological characterizations of the same human tissue sample. Histological evaluation of the cellular and extracellular matrix of the human vessels verified that the dynamic moduli and Poison's ratio tests were nondestructive. Fluid absorption by VC‐A30 showed statistically significant softening of mechanical properties, stabilizing after 4 days in phosphate‐buffered saline (PBS). Human vasculature exhibited notably similar results to VC‐A30 in five of eight mechanical tests (≤30% difference) versus two of eight for standard silicone (≤38% difference). Results show that VC‐A30 provides a new option for 3D‐printing translucent in vitro vascular models with anatomically relevant mechanical properties. These new vessel analogs may simulate patient‐specific vessel disease states, improve surgical training models, accelerate new endovascular device developments, and ultimately reduce the need for animal models.


  • Open Access

    Definitions of intracranial aneurysm size and morphology: A call for standardization

    by William C. Merritt, Holly F. Berns, Andrew F. Ducruet, Timothy Andrew Becker

    Background: Intracranial aneurysms (IAs) are classified based on size (maximal dome diameter) as well as additional parameters such as neck diameter and dome-to-neck ratio (DNR). The neurosurgical literature includes a wide variety of definitions for both IA size and neck classifications. Standardizing the definitions of IA size and wide-neck classifications would help eliminate inconsistencies and potential misunderstandings of aneurysm morphology and rupture risk. Methods: We queried the MEDLINE (EBSCO) database using the terms “unruptured IA” and (“small” or “medium” or “large”) and filtered based on publication date, language, and scholarly journals. The resulting articles and their references were further screened for eligibility. This identified 286 records, of which 104 were excluded, leaving 182 articles for analysis. The review found several different IA size classifications and neck classifications. Results: A review of the existing literature describing size and neck classifications revealed 13 size classifications for small aneurysms, four classifications for medium aneurysms, 15 classifications for large aneurysms, and one classification for giant aneurysms. There were also seven different wide-neck classifications found. Conclusion: It is imperative that a standardization in classification be implemented to help interventionalists make the most informed decisions regarding emerging treatment options as new endovascular technologies and devices are emerging with indications based around these classifications. Based on the database findings, this article recommends standardized quantitative measurement ranges for IA size and neck classifications.


  • Open Access

    Application of a rabbit-elastase aneurysm model for preliminary histology assessment of the PPODA-QT liquid embolic

    by April Huckleberry, William Merritt, Trevor Cotter, Christopher Settanni, Mark C. Preul, Andrew F. Ducruet, Timothy Andrew Becker

    Background: PPODA-QT is a novel liquid embolic under development for the treatment of cerebral aneurysms. We sought to test the rabbit-elastase aneurysm model to evaluate the tissue response following PPODA-QT embolization. Methods: Experimental elastase-induced aneurysms were created in fourteen New Zealand White Rabbits. Eight animals were used for aneurysm model and endovascular embolization technique development. Six PPODA-QT-treated animals were enrolled in the study. Control and aneurysm tissues were harvested at acute (n = 2), 1-month (n = 2), and 3-month (n = 2) timepoints and the tissues were prepared for histology assessment. Results: All fourteen rabbit-elastase aneurysms resulted in small and medium aneurysm heights (d: n) ratios. Histological evaluation of four aneurysms, treated with PPODA-QT, demonstrated reorganization of aneurysm wall elastin into a smooth muscle layer, and observed as early as the 1-month survival timepoint. At the aneurysm neck, a homogenous neointimal layer (200–300 μm) formed at the PPODA-QT interface, sealing off the parent vessel from the aneurysm dome. No adverse immune response was evident at 1- and 3-month survival timepoints. Conclusion: PPODA-QT successfully embolized the treated aneurysms. Following PPODA-QT embolization, neointimal tissue growth and remodeling were noted with minimal immunological response. The experimental aneurysms created in rabbits were uniformly small with inconsistent neck morphology. Further testing of PPODA-QT will be conducted in larger aneurysm models for device delivery optimization and aneurysm healing assessment before human clinical investigation.